Jefferies analyst Eun Yang upgraded CureVac to Buy from Hold with a price target of $21, up from $9, after the company announced preliminary data from its ongoing Phase 1 clinical programs in COVID-19 and seasonal flu. The tested vaccine candidates are being developed in collaboration with GSK.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CVAC: